Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio's CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.
馬薩諸塞州沃爾瑟姆，2024年11月21日（GLOBE NEWSWIRE）——Upstream Bio, Inc.（納斯達克股票代碼：UPB）是一家臨床階段的公司，最初專注於嚴重呼吸系統疾病。該公司今天宣佈，Upstream Bio首席執行官蘭德·薩瑟蘭將於2024年12月3日下午2點參加派珀·桑德勒第36屆年度醫療保健會議的爐邊談話 .Et。
A live webcast of the presentation will be available under the "Events" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
活動當天，將在公司網站 「投資者」 頁面的 「活動」 選項卡下觀看演講的網絡直播。網絡直播的重播將在演示結束後的90天內在公司網站上存檔。
About Upstream Bio
關於上游生物
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .
Upstream Bio是一家臨床階段的生物技術公司，開發炎症性疾病的治療方法，最初的重點是嚴重的呼吸系統疾病。該公司正在開發verekitug，這是目前唯一已知的靶向胸腺基質淋巴生成素受體的拮抗劑。胸腺基質淋巴生成素是一種經過臨床驗證的炎症反應驅動因素，位於影響各種免疫介導疾病的多個信號級聯的上游。該公司已將這種高效的單克隆抗體推進到單獨的2期試驗，用於使用鼻息肉治療嚴重哮喘和慢性鼻竇炎，並計劃啓動慢性阻塞性肺病的開發。Upstream Bio的團隊致力於最大限度地發揮verekitug的獨特特性，以解決當今標準護理服務不足的患者大量未得到滿足的需求。要了解更多信息，請訪問。
CONTACT: Investor Contact:
Michael Gray
Chief Financial Officer and Chief Operating Officer
ir@upstreambio.com
Media Contact:
Teri Dahlman
Red House Communications
teri@redhousecomms.com
聯繫人：投資者聯繫人：
邁克爾·格雷
首席財務官兼首席運營官
ir@upstreambio.com
媒體聯繫人：
泰瑞·達爾曼
紅屋通訊
teri@redhousecomms.com
